• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prevention of chronic HBV infection induced hepatocellular carcinoma development by using antiplatelet drugs.

作者信息

Lee Kuan-Han, Wu Chin-Jen, Wang Clay C C, Hung Jui-Hsiang

机构信息

Institute of Pharmaceutical Science, Chia Nan University of Pharmacy and Science, Tainan, Taiwan; ; Drug Discovery and Development Center, Chia Nan University of Pharmacy and Science, Tainan, Taiwan;

Department of QC/R&D, Kaiser Pharmaceutical CO., LTD., Tainan, Taiwan;

出版信息

Hepatobiliary Surg Nutr. 2012 Dec;1(1):57-8. doi: 10.3978/j.issn.2304-3881.2012.10.09.

DOI:10.3978/j.issn.2304-3881.2012.10.09
PMID:24570904
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3924632/
Abstract
摘要

相似文献

1
Prevention of chronic HBV infection induced hepatocellular carcinoma development by using antiplatelet drugs.使用抗血小板药物预防慢性乙型肝炎病毒感染诱发的肝细胞癌发展
Hepatobiliary Surg Nutr. 2012 Dec;1(1):57-8. doi: 10.3978/j.issn.2304-3881.2012.10.09.
2
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.抗血小板治疗可预防乙型肝炎慢性模型小鼠的肝细胞癌并改善其生存。
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72. doi: 10.1073/pnas.1209182109. Epub 2012 Jul 2.
3
Interferon signaling during Hepatitis B Virus (HBV) infection and HBV-associated hepatocellular carcinoma.乙型肝炎病毒 (HBV) 感染期间的干扰素信号转导与 HBV 相关的肝细胞癌。
Cytokine. 2019 Dec;124:154518. doi: 10.1016/j.cyto.2018.08.012. Epub 2018 Aug 17.
4
Hepatocellular carcinoma: could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?肝细胞癌：抗血小板药物可用于预防乙肝相关的肝细胞癌吗？
Nat Rev Gastroenterol Hepatol. 2012 Aug;9(8):425. doi: 10.1038/nrgastro.2012.139. Epub 2012 Jul 17.
5
Risk of hepatocellular carcinoma and cancers at other sites among patients diagnosed with chronic hepatitis B virus infection in Sweden.瑞典慢性乙型肝炎病毒感染者的肝细胞癌和其他部位癌症风险。
J Med Virol. 2014 Jan;86(1):18-22. doi: 10.1002/jmv.23754. Epub 2013 Sep 13.
6
Review article: the prevention of hepatitis B-related hepatocellular carcinoma.综述文章：乙型肝炎相关肝细胞癌的预防。
Aliment Pharmacol Ther. 2018 Jul;48(1):5-14. doi: 10.1111/apt.14683. Epub 2018 May 3.
7
Epidemiology of chronic hepatitis B virus infection, hepatocellular carcinoma, and hepatitis B virus-induced hepatocellular carcinoma.慢性乙型肝炎病毒感染、肝细胞癌及乙型肝炎病毒所致肝细胞癌的流行病学
Pathol Biol (Paris). 2010 Aug;58(4):273-7. doi: 10.1016/j.patbio.2010.01.005. Epub 2010 Apr 7.
8
Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection.肝细胞癌：其生长的分子生物学及其与乙型肝炎病毒感染的关系
Med Clin North Am. 1989 Jul;73(4):985-97. doi: 10.1016/s0025-7125(16)30649-6.
9
PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma.PRDM1 水平与慢性 HBV 感染中的临床疾病及 HBV 相关肝细胞癌患者的生存相关。
Int Immunopharmacol. 2019 Aug;73:156-162. doi: 10.1016/j.intimp.2019.05.012. Epub 2019 May 14.
10
Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma.综述文章：乙型肝炎病毒感染的免疫接种与肝细胞癌的预防
Aliment Pharmacol Ther. 2021 Jun;53(11):1166-1182. doi: 10.1111/apt.16356. Epub 2021 Apr 28.

引用本文的文献

1
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.巴塞罗那临床肝癌C期肝细胞癌患者肝切除术后辅助使用索拉非尼。
World J Gastroenterol. 2016 Jun 21;22(23):5384-92. doi: 10.3748/wjg.v22.i23.5384.
2
Hepatitis B virus infection status is an independent risk factor for multiple myeloma patients after autologous hematopoietic stem cell transplantation.乙肝病毒感染状态是自体造血干细胞移植后多发性骨髓瘤患者的独立危险因素。
Tumour Biol. 2013 Jun;34(3):1723-8. doi: 10.1007/s13277-013-0709-z. Epub 2013 Feb 23.
3
Evaluation of seven different staging systems for alpha-fetoprotein expression in hepatocellular carcinoma after hepatectomy.肝切除术后肝细胞癌甲胎蛋白表达的七种不同分期系统的评估
Tumour Biol. 2013 Apr;34(2):1061-70. doi: 10.1007/s13277-013-0646-x. Epub 2013 Jan 16.

本文引用的文献

1
Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease.乙型肝炎病毒相关肝病患者的血小板定量异常
Gastroenterology Res. 2009 Dec;2(6):344-349. doi: 10.4021/gr2009.12.1329. Epub 2009 Nov 20.
2
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.抗血小板治疗可预防乙型肝炎慢性模型小鼠的肝细胞癌并改善其生存。
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72. doi: 10.1073/pnas.1209182109. Epub 2012 Jul 2.
3
Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells.乙型肝炎病毒前 S2 区突变型大表面蛋白诱导 Bcl-2 表达增强对 Huh-7 细胞 5-氟尿嘧啶耐药性的影响。
PLoS One. 2011;6(12):e28977. doi: 10.1371/journal.pone.0028977. Epub 2011 Dec 22.
4
Immune effectors required for hepatitis B virus clearance.清除乙型肝炎病毒所需的免疫效应物。
Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):798-802. doi: 10.1073/pnas.0913498107. Epub 2009 Dec 22.
5
Regulation of platelet functions by P2 receptors.P2受体对血小板功能的调节
Annu Rev Pharmacol Toxicol. 2006;46:277-300. doi: 10.1146/annurev.pharmtox.46.120604.141207.
6
Platelets mediate cytotoxic T lymphocyte-induced liver damage.血小板介导细胞毒性T淋巴细胞诱导的肝损伤。
Nat Med. 2005 Nov;11(11):1167-9. doi: 10.1038/nm1317. Epub 2005 Oct 30.
7
Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia.远东和东南亚地区肝细胞癌疾病负担的变化
Liver Int. 2005 Aug;25(4):696-703. doi: 10.1111/j.1478-3231.2005.01139.x.
8
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.阿司匹林与氯吡格雷：疗效、安全性及耐药性问题
Arterioscler Thromb Vasc Biol. 2004 Nov;24(11):1980-7. doi: 10.1161/01.ATV.0000145980.39477.a9. Epub 2004 Sep 23.
9
Molecular pathogenesis of human hepatocellular carcinoma.人类肝细胞癌的分子发病机制
Nat Genet. 2002 Aug;31(4):339-46. doi: 10.1038/ng0802-339.
10
Genetic mechanisms of hepatocarcinogenesis.肝癌发生的遗传机制。
Oncogene. 2002 Apr 11;21(16):2593-604. doi: 10.1038/sj.onc.1205434.